Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.

Category	Detail
Condition	Chronic Spontaneous Urticaria (CSU)
Key Mechanisms	Dupilumab blocks signaling through the shared receptor for interleukin-4 and interleukin-13, reducing type 2 inflammation.
Target Population	Patients aged 6 to 80 years with CSU symptoms persisting despite antihistamine therapy.
Care Setting	Multicenter, randomized, double-blind, placebo-controlled clinical trial.

Dupilumab showed greater reductions in itch severity and urticaria activity compared to placebo.
70% of dupilumab-treated patients achieved at least a 5-point reduction in itch severity.
Pooled analysis indicated 43% of dupilumab patients achieved well-controlled disease.
Safety outcomes were similar between dupilumab and placebo groups.
Dupilumab treatment resulted in significant reductions in serum immunoglobulin E concentrations.

Chronic spontaneous urticaria is diagnosed based on recurrent pruritic wheals and angioedema lasting more than 6 weeks.

Dupilumab is recommended for patients with CSU who remain symptomatic despite antihistamine therapy.

Monitor for treatment-emergent adverse events, including nasopharyngitis and injection-site reactions.

Patients with CSU aged 6 to 80 years, symptomatic despite stable antihistamine treatment.

Dupilumab dosing is weight-based, administered subcutaneously every 2 or 4 weeks.

Consider dupilumab for patients with CSU unresponsive to standard antihistamine therapy.
Evaluate treatment response at 24 weeks to assess efficacy.

Clinical Scorecard: Dupilumab Faces Trial in Chronic Hives